Time to recovery – Page 2 – Communicable Diseases Research

Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

Clinical Trial

Published on 2022-04-082022-10-05
Journal: Critical Care [Category] COVID19(2023년), SARS, 임상,

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Clinical Trial

Published on 2022-04-012022-10-04
Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, 치료법,

[키워드] 1:1 A significant reduction all-cause mortality assigned Baricitinib baseline Blood clots Brazil cardiovascular event Care Cohort Combination company conducted Corticosteroids Critically ill death died double-blind duration of hospitalisation Efficacy efficacy analysis Efficacy and safety Endpoint enrolled evaluate event exploratory extracorporeal membrane oxygenation hazard ratio hospital hospitalised hospitalised patient infections inhibitor intention-to-treat population Invasive mechanical ventilation investigator Janus kinase laboratory-confirmed SARS-CoV-2 infection less Lilly membrane Mortality not differ participant Participants Patient Phase 3 phase 3 trial Placebo placebo-controlled trial placebo-treated participant prevented randomised Randomly receiving reduced reduction Registered risk reduction safety analysis safety population SARS-COV-2 infection selective severely ill patient shown significantly significantly shorter Standard Standard of care Study design study group study population systemic corticosteroid the placebo group Time to recovery Treatment treatment group treatment groups Trial USA ventilator-free day Ventilator-free days was done with COVID-19
[DOI] 10.1016/S2213-2600(22)00006-6 PMC 바로가기 [Article Type] Clinical Trial

Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial

중등도 COVID-19 감염으로 입원한 환자를 위한 글리시리진 및 보스웰산 병용 치료: 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-03-012022-09-10
Journal: Inflammopharmacology [Category] COVID19(2023년), SARS, 변종, 임상,

[키워드] Advancing Adverse adverse events age Anti-inflammatory Antiviral assigned Boswellic aids clinical clinical status Clinical status score Combination combination treatment COVID-19 death diagnosed double-blind drugs Efficacy eligibility eligible Enrollment evaluated event Evidence FIVE glycyrrhizin hospital hospitalized patient hospitalized patients Identifier immunomodulating Infection institutional protocol IQR matching placebo median median age Mild mild to moderate moderate Moderate COVID-19 moderate infection moderate symptoms Mortality mortality rate outcome Patient PCR test Placebo placebo group placebo-controlled Primary outcome Randomized randomized clinical trial randomized trial Randomly receive receiving recent Recovery time Registered required Safe SARS-CoV-2 secondary secondary outcome significant decrease significant difference significantly shorter single-center small sample size study drug Symptoms the placebo group therapeutic Time to recovery Treatment treatment of COVID-19 Trial university variant variants
[DOI] 10.1007/s10787-022-00939-7 PMC 바로가기 [Article Type] Randomized Controlled Trial

Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients

Observational Study

Published on 2022-03-012022-10-04
Journal: European Journal of Hospital Pharmacy [Category] SARS, 임상,

[키워드] activities Admission Adverse adverse event age Anti-inflammatory Baricitinib C-reactive protein clinical clinical benefit Clinical improvement Corticosteroid COVID-19 Critical Critical care Cytokine storm syndrome education Effectiveness event Evidence-based medicine ferritin hospital discharge hospitalised hospitalised patient immunomodulator improvement inhibitor interleukin-6 IQR laboratory parameter limitation Lymphocytes men Patient Pharmacy Platelet poor prognosis pulmonary medicine Randomised trial reported Retrospective study risk factor severe COVID-19 survival Time to recovery treated Treatment viral endocytosis Virology
[DOI] 10.1136/ejhpharm-2021-002741 PMC 바로가기 [Article Type] Observational Study

Epidemiology, clinical characteristics and risk factors of COVID-19 among children in Saudi Arabia: a multicenter chart review study

Research

Published on 2022-02-122022-10-28
Journal: BMC Pediatrics [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS,

[키워드] 95% CI accounted addition Admission Adults affected calculated carried Characteristics children Clinical characteristics Clinical severity condition conducted country Course COVID-19 COVID-19 case cross-sectional develop disease disease severity enrolled epidemiological Factor higher risk initial intensive care unit invasive ventilation less Logistic regression analysis lung males Mild MIS-C coronavirus, Coronaviridae moderate-to-severe COVID-19 Mortality MOST multicenter multivariate outcome Patient pediatric Pediatric patient predictor Prognosis RBC RBCs red blood cell regression analysis reported symptom required Result Retrospective study risk factor SARS-2 SARS-COV-2 infection Saudi Arabia supplementary material Time to recovery
[DOI] 10.1186/s12887-021-02959-8 PMC 바로가기 [Article Type] Research

A modified Susceptible-Infected-Recovered model for observed under-reported incidence data

Research Article

Published on 2022-02-092022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS,

[키워드] America Analysis asymptomatic individual Bayesian Brazil chain conditional distribution develop disease incidence distribution eight example fitting fixed fraction incidence infected individual Markov outbreak parameter reported resulting reveal the United State Time to recovery transmission rate
[DOI] 10.1371/journal.pone.0263047 PMC 바로가기 [Article Type] Research Article

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

COVID-19에 대한 항 바이러스 요법의 효능 : 무작위 대조 시험의 체계적인 검토

Research

Published on 2022-01-312022-09-10
Journal: BMC Infectious Diseases [Category] SARS, 임상, 치료제,

[키워드] Administered Antiviral antiviral therapy Antiviral treatment approved article Clinical improvement clinical outcomes controlled trials coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 mortality COVID-19 patients COVID-19 treatment daclatasvir demonstrated Descriptive statistics disease course effective Efficacy Evidence examined exhibited guideline heterogeneity identify improve clinical outcome include inferential statistics network not performed patients performed public health randomized clinical trial randomized clinical trials Randomized controlled trial Randomized controlled trials RCT reducing reducing mortality Remdesivir Result retrieved SARS-CoV-2 Scottish sofosbuvir sofosbuvir/daclatasvir Statistical power study heterogeneity suggested supplementary material systematic literature search systematic review the disease therapeutic Time to recovery Treatment trials was performed were excluded were expressed
[DOI] 10.1186/s12879-022-07068-0 PMC 바로가기 [Article Type] Research

A review of remdesivir for COVID-19 in pregnancy and lactation

임신 및 수유 중인 코로나19에 대한 렘데시비르 검토

Review

Published on 2021-12-242022-09-11
Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제,

Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19

COVID-19 환자에서 입원 전 증상 기간에 따른 렘데시비르의 영향

Article

Published on 2021-11-122022-09-11
Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제,

Does the data tell the true story? A modelling assessment of early COVID-19 pandemic suppression and mitigation strategies in Ghana

Research Article

Published on 2021-10-292022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS,